Design Therapeutics Inc   (DSGN)
Other Ticker:  
Price: $2.1900 $-0.03 -1.351%
Day's High: $2.24 Week Perf: -1.79 %
Day's Low: $ 2.15 30 Day Perf: 5.8 %
Volume (M): 412 52 Wk High: $ 15.19
Volume (M$): $ 902 52 Wk Avg: $5.85
Open: $2.24 52 Wk Low: $1.94

 Market Capitalization (Millions $) 123
 Shares Outstanding (Millions) 56
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -72
 Cash Flow (TTM) (Millions $) -15
 Capital Exp. (TTM) (Millions $) 1

Design Therapeutics Inc
Design Therapeutics Inc is a biotechnology company that is focused on developing transformative treatments for serious degenerative conditions that are caused by RNA dysregulation. The company was founded in 2017 by two leading RNA-targeting scientists from Scripps Research, Matthew Disney, PhD, and Adrian Krainer, PhD, along with entrepreneur Jean-Pierre Sommadossi, PhD, who serves as the CEO.

Design Therapeutics is headquartered in San Diego, California and is primarily focused on developing small molecule drugs that specifically target RNA molecules that are malfunctioning in a variety of disease states. RNA is a critical component of gene expression and can play a causal role in many diseases, including neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and Parkinson's disease, as well as genetic disorders such as myotonic dystrophy.

The company has a proprietary platform technology called 'DTx RNA Targeting Platform' that enables precision medicine technologies for rigorous target identification and selection followed by the design precise small molecules as potential therapeutics. The platform encompasses in-depth genomics data, small molecule pharmacological properties, and proprietary algorithms for identifying potential RNA targets.

One of the lead programs for Design Therapeutics is in the development of DM1, a small molecule investigational therapy for myotonic dystrophy type 1 (DM1). DM1 is an inherited neuromuscular disorder that affects multiple organs and systems of the body, including the nervous system, heart, and muscle. There is currently no cure for DM1, only supportive therapies for the symptoms. Design Therapeutics is focused on developing a small molecule DM1 drug candidate that selectively inhibits the abnormal protein produced by DM1's genetic mutation.

Furthermore, Design Therapeutics has various collaborations with other biotech companies and institutions. In 2021, it announced a partnership with Regeneron to utilize its precision medicine platform towards discovering RNA-targeting therapeutics.

In summary, Design Therapeutics Inc is a biotechnology company that is focused on developing small molecule drugs that target RNA molecules that are implicated in degenerative diseases, with emphasis on neuromuscular disorders. With a proprietary platform technology and an experienced team, the company aims to bring transformative treatments to the clinic.

   Company Address: 6005 Hidden Valley Road Carlsbad 92011 CA
   Company Phone Number: 293-4900   Stock Exchange / Ticker: NASDAQ DSGN
   DSGN is expected to report next financial results on March 13, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Overcomes Revenue Setback, Prepares for Resurgence in Q4 2023

Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.

Procyon Corporation

Procyon Corporation Steams Ahead, Consolidating Revenue at PCYN in Record-breaking Quarter

Based on the financial time-frame ending September 30, 2023, Procyon Corporation has experienced significant declines and challenges, leading to a bearish outlook for the company. Depleting orders have played a crucial role in the losses incurred during this period.
The revenue for Procyon Corporation fell by -0.221% to $1.17 million compared to the previous reporting season, where revenue decreased by -2.42% from $1.20 million. This downward trend indicates a constant struggle for the company to maintain a steady revenue stream. It is clear that Procyon Corporation has been facing difficulties in generating consistent income.

China Health Industries Holdings Inc

Impressive 11.069% Revenue Surge Demonstrates China Health Industries Holdings Inc's Strong Growth Potential in Q3 2023

China Health Industries Holdings Inc (CHHE) recently announced its financial results for the fiscal period ending September 30, 2023. These results demonstrate the company's ability to achieve top-line growth despite industry-wide revenue reductions. Additionally, CHHE's inventories have declined, indicating potential future demand. This article will outline the facts and set the current financial results into context.
Financial Results Overview:
For the fiscal period ending September 30, 2023, CHHE reported a zero gain of $0.00 per share, compared to a loss of $0.01 per share during the same period a year ago. Sequentially, CHHE improved from a loss of $0.01 per share in the previous quarter. This indicates progress in generating profits and more favorable financial performance.

Acer Therapeutics Inc

Acer Therapeutics Inc Reports Revenue of $0.37179 Million in Q3 2023 Financial Report amidst Concerns of Declining Stock Performance

The stock performance of a company plays a vital role in determining its overall financial health. Acer Therapeutics Inc, a major player in the pharmaceutical preparations industry, has experienced a decline in its stock price over the past week, negatively impacting its year-to-date performance. This article aims to provide an overview of the recent trends seen in Acer Therapeutics Inc's stock performance, along with insights into the company's financial records and future expectations.
Stock Performance
Over the past week, Acer Therapeutics Inc's stock has experienced a decline, although the exact percentage decrease is undisclosed in the provided information. This downtrend has brought the company's year-to-date performance to a staggering -74.81%. Consequently, investors may have concerns about the company's financial stability, prompting a closer examination of its financial records.

Baudax Bio Inc

Baudax Bio Inc's Revenue Shows Steady Comparison to Previous Year During July-September 2023 Period

Baudax Bio Inc, a pharmaceutical company listed on the NASDAQ, recently released its financial results for the July to September 2023 period. The company demonstrated significant improvements in its loss per share and earnings per share compared to the previous year and the previous quarter. Despite revenue remaining unchanged, Baudax Bio Inc reported a substantial decrease in its net shortfall. This article aims to outline the facts and interpret these financial results.
1. Improving Financial Performance:
For the July to September 2023 period, Baudax Bio Inc managed to decrease its loss per share from $-2.47 to $-0.30 when compared to the same quarter last year, showcasing a remarkable improvement. Moreover, earnings per share saw significant growth from $-1.51 in the previous quarter to the current quarter.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com